Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

BACKGROUND: Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic activity and high sustained virologic response (SVR) rates in studies outside Japan. Here we report safety and efficacy in a subset of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumada, Hiromitsu, Watanabe, Tsunamasa, Suzuki, Fumitaka, Ikeda, Kenji, Sato, Ken, Toyoda, Hidenori, Atsukawa, Masanori, Ido, Akio, Takaki, Akinobu, Enomoto, Nobuyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David, Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866827/
https://www.ncbi.nlm.nih.gov/pubmed/29052790
http://dx.doi.org/10.1007/s00535-017-1396-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866827/
https://www.ncbi.nlm.nih.gov/pubmed/29052790
http://dx.doi.org/10.1007/s00535-017-1396-0

Ejemplares similares